Skip to main content
79°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
59.63
+0.89 (+1.52%)
Streaming Delayed Price
Updated: 12:50 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
Next >
Key Takeaways From Legend Biotech Analyst Ratings
December 19, 2023
Via
Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
December 11, 2023
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or
Via
Benzinga
Earnings Scheduled For November 20, 2023
November 20, 2023
Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.
Via
Benzinga
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Analyst Ratings for Legend Biotech
October 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Legend Biotech
August 16, 2023
Via
Benzinga
The Latest Analyst Ratings for Legend Biotech
July 20, 2023
Via
Benzinga
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug
October 18, 2023
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,
Via
Benzinga
3 Biotech Stocks That Analysts Are Drooling Over
August 07, 2023
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.
Via
InvestorPlace
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
June 20, 2023
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.
Via
Investor's Business Daily
The Latest Analyst Ratings for Legend Biotech
June 13, 2023
Via
Benzinga
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
June 10, 2023
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...
Via
Talk Markets
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast
June 06, 2023
Via
Benzinga
Expert Ratings for Legend Biotech
May 25, 2023
Via
Benzinga
Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share
May 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
May 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
May 22, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 10, 2023
Via
Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
May 02, 2023
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen
Via
Benzinga
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?
May 01, 2023
Legend's cell therapy seems like it's a winner, but it might be priced in already.
Via
The Motley Fool
Potential Breakout Setups To Watch On Wednesday
April 26, 2023
The U.S. stock market has weakened throughout Tuesday’s trading session and the major indices were sitting near session lows heading into the closing bell.
Via
Benzinga
Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study Results
April 21, 2023
Legend Bio is on a run on excitement for its multiple myeloma treatment.
Via
Investor's Business Daily
Why Shares of Geron Are Up 30% This Week
April 20, 2023
The company's CEO was scheduled to speak at a virtual conference on Thursday.
Via
The Motley Fool
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
April 20, 2023
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 19, 2023
Via
Benzinga
Why Shares of Legend Biotech Jumped Wednesday
April 19, 2023
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.
Via
The Motley Fool
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 19, 2023
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.